Published on 29 Dec 2023 on Simply Wall St. via Yahoo Finance
Fate Therapeutics Insiders US$207k Short Of Breakeven On Stock Purchase
Insiders who bought US$698.1k worth of Fate Therapeutics, Inc. (NASDAQ:FATE) stock in the last year have seen some of their losses recouped as the stock gained 18% last week. The purchase, however, has proven to be a pricey bet, with losses currently totalling US$207k.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
View our latest analysis for Fate Therapeutics